Abstract 1886
Background
Knowledge of molecular abnormalities in haematological malignancies led to better understanding of their role in disease development, progression and resistance to treatments. However, effective impact of NGS analyses need to be evaluated. RuBIH2 programme aims to determine appropriate prescription, clinical utility and validity, cost and territorial organisation of NGS under a governmental funded “Programme de Recherche Médico-Economique” (Health Economics Research Program).
Methods
We considered 5 haematological malignancies: myelodysplasia, acute lymphoid leukaemia, acute myeloid leukaemia, lymphoma and lymphoproliferative disorders and myeloproliferative disorders. 26 French biomolecular platforms are involved. The program is split into 4 work packages (WP). WP1: micro-costing, WP2: appropriate prescribing guidelines, WP3: evaluation of clinical validity, WP4: recommendations on national organization.
Results
WP1: is a micro-costing of NGS on 5 biomolecular platforms to assess production cost depending on the volume of analyses performed, type of pathology and panel size. Based on a bottom-up approach and onsite observations, we calculated an average mean cost. WP2: is to define recommended diagnostic tests according to pathologies and patients’ characteristics. National key opinion leaders (clinicians and biologists) defined a NGS minimal panel depending on therapeutic possibilities. Biological analyses performed at diagnosis, relapse or during follow-up will be classified as mandatory, recommended, under evaluation or obsolete. WP3: is a real-world data study of NGS analyses carried out by 26 biomolecular platforms. Biological and clinical information are collected in an eCRF. Analysis will describe the impact of NGS on patients’ pathways. WP4: will integrate data collected during WP 1-3 to define an optimal national organization and bundled payment scheme.
Conclusions
Final objective is to improve patient care and access to NGS based on better stratification and definition of analyses to perform at each stage of patient’s care pathways: diagnostic, relapse and follow-up.
Clinical trial identification
NCT03750994.
Editorial acknowledgement
Legal entity responsible for the study
Assistance Publique Hôpitaux de Paris.
Funding
Direction Générale de l’Offre de Soins (DGOS) - French Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5152 - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study
Presenter: Eleonora Bergo
Session: Poster Display session 1
Resources:
Abstract
4079 - Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Presenter: Gabriela Kramer-marek
Session: Poster Display session 1
Resources:
Abstract
4364 - Upregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma
Presenter: Gema Bruixola
Session: Poster Display session 1
Resources:
Abstract
2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas
Presenter: Itai Moshe
Session: Poster Display session 1
Resources:
Abstract
3154 - Preclinical Study of Novel Tetracyclic Small Molecule, CC12, for Brain Cancer
Presenter: Liyun Fann
Session: Poster Display session 1
Resources:
Abstract
5759 - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma
Presenter: Inge Compter
Session: Poster Display session 1
Resources:
Abstract
1382 - A Phase II Clinical Trial Evaluating the Efficacy and Safety of Apatinib Combined with dose-dense Temozolomide in Recurrent Glioblastoma
Presenter: Yong Wang
Session: Poster Display session 1
Resources:
Abstract
4407 - Phase 0 Trial of Ceritinib in Brain Metastases and Recurrent Glioblastoma
Presenter: Shwetal Mehta
Session: Poster Display session 1
Resources:
Abstract
1469 - Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): an observational study
Presenter: Mario Caccese
Session: Poster Display session 1
Resources:
Abstract
4217 - Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): a single-center experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract